Latest news with #TheUniversityofTexasHealthScienceCenter
Time Business News
24-07-2025
- Health
- Time Business News
Advancements in Genetically Engineered Models for Precision Research
A mice model refers to laboratory mice that are genetically engineers or breeds to study human diseases, drug reactions and biological processes. These models are widely used in biomedical research, due to their genetic similarity for humans, small reproductive cycles and ease of handling. The model of mice market growth is inspired by increasing demand for preclinical study, increase in drug discovery and investment in cancer research, progress in genetic engineering technologies such as CRISPR and increasing attention to individual medicine. Additionally, the requirement of accurate and cost-effective models for the study of complex diseases enhances the adoption of models of innovative and humanized mice. Key Growth Drivers and Opportunities Rising Demand for Preclinical Studies: The growing demand for preclinical studies is significantly increasing the growth of the market model of mice, as laboratory mice are essential tools in evaluating new drugs and remedies before human tests. Pharmaceutical and biotechnology companies greatly rely on the models of mice to stimulate human diseases, test drug candidates and assess biological reactions in a controlled environment. There is a growing requirement of models of exact, reliable and genetically engineer mice, especially in oncology, neurology and genetic disorders, with R&D investment. This bounce in pregnancy research accelerates the demand for models of advanced and human-to-human mice, fuel the expansion of the market and innovation. Challenges The mice models face many boundaries in the market that can obstruct its growth and effectiveness. A major challenge is a biological difference between mice and humans, which can lead to incorrect predictions of human reactions to drugs or diseases, limiting the translation value of research. Additionally, moral concerns about animal testing, with strict regulatory guidelines, can restrict the experiment and increase research costs. High maintenance and reproductive costs, especially for models of genetically modified or human rats, also create financial obstacles for small research institutes. In addition, increasing availability of optional in in vitro and computational models can reduce dependence on animal models over time. Innovation and Expansion Researchers Created the First Completely Working Human Immune System Mouse Model In July 2024, A biological research discovery offers fresh perspectives on disease modeling and immunotherapy development. Researchers at The University of Texas Health Science Center in San Antonio have developed a humanized mouse model that can mount certain antibody responses because it has a human immune system and a gut flora similar to that of humans. The multi-year effort, which was published in the August 2024 issue of Nature Immunology, aimed to build a humanized mouse with a fully functional human immune system in order to overcome the limits of the in vivo human models that are currently available. The resultant humanized mice, known as TruHuX (for truly human, or THX), have a complete and functional human immune system, complete with lymph nodes, germinal centers, human T and B lymphocytes, memory B lymphocytes, thymus human epithelial cells, and plasma cells that produce highly specific antibodies and autoantibodies that are exactly like those found in humans. The RenMice Series for Advanced Drug Discovery is Officially Launched by Biocytogen In September 2023, The RenMice series, which consists of a set of independently created, completely human antibody mice and TCR mice with exclusive intellectual property, was formally disclosed by Biocytogen Pharmaceuticals Co., Ltd. As 'human,' the term 'Ren' is derived from the Chinese pinyin for '人' (rén), which incorporates Eastern cultural elements and symbolizes Biocytogen's dedication to creating cutting-edge technologies that promote the discovery, development, and delivery of novel therapeutics, ultimately improving human health. RenMab, RenLite, RenNano, RenTCR, and RenTCR-mimic are the five strains of completely human antibody/TCR mice that make up the RenMice line. completely human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, completely human T-cell receptors (TCRs), and TCR-mimic antibodies have all been found using these animals. Inventive Sparks, Expanding Markets The key players operating in the mice model market include Charles River Laboratories, (US) The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Envigo (US), JANVIER LABS (France), genOway (France), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioservices (France), Ingenious Targeting Laboratory (US), Cyagen Biosciences (US), GVK BIO (India), The Andersons, Inc. (US), Innovive (US), Allentown, LLC (US), FENGSHI Group (China), Ozgene Pty Ltd. (Australia), and Harbour Biomed (US). About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Time Business News
22-07-2025
- Health
- Time Business News
Breakthroughs in Humanized Mouse and Rat Model Technologies
Humanized mouse and rat models are laboratory rodents genetically engineers to carry human genes, cells, tissues, or immune systems, which enable researchers to study human-specific diseases, immune reactions, and effects of drugs in a living organism. The market is growing rapidly for these models due to rising demand for more predictive preclinical tools in oncology, infectious diseases and immunotherapy research. As traditional animal models often fail to mimic the accurate mimic of human biology, humanized rodents provided a more reliable platform for drug development, personal medical and translation research, which runs their adoption in drugs and educational fields. Key Growth Drivers and Opportunities Infectious Diseases and Immunotherapy Research: Increasing prevalence of infectious diseases and rapid expansion of immunotherapy research are the major driver of the humanized mouse and rat model market, as these models closely mimic human immune responses and disease progression. They provide an important platform to evaluate vacancies, antiviral drugs and immune-based treatments in human-affected context. With the increasing demand for individual and targeted remedies, especially in oncology and virology, the requirement of an exact pre -pricing model is rapidly growing, leading to indispensable equipment in translation and drug development research to human rodents. Challenges Humanized mouse and rat model market face high production costs, technical complexity in genetic engineering and limited enclosure efficiency of human cells or tissues in some models. Additionally, these rodents are not fully repeated to all aspects of human physiology, causing the disease progression and discrepancies in the reaction of the drug. Moral concerns and regulatory barriers also face challenges, especially in studies associated with human immune components or fetal tissue, potentially slow down widespread adoption and commercialization. Innovation and Expansion Researchers Create the First Whole Humanized Immune System in a Mouse Model In July 2024, Researchers at The University of Texas Health Science Center in San Antonio have developed a humanized mouse model that can mount certain antibody responses because it has a human immune system and a gut flora similar to that of humans. The multi-year effort, which was published in the August 2024 issue of Nature Immunology, aimed to build a humanized mouse with a fully functional human immune system in order to overcome the limits of the in vivo human models that are currently available. Human T and B lymphocytes, memory B lymphocytes, lymph nodes, germinal centers, thymus human epithelial cells, and plasma cells that produce highly specific antibodies and autoantibodies that are identical to those of humans are all present in the resulting humanized mice, known as TruHuX. Biologics UK Presents GemPharmatech's Humanized Mouse Models for COVID-19 and Bispecific Antibody Research In September 2021, At the Biologics UK Oxford Global Conference, held September 6–8, 2021, in London, UK, GemPharmatech co-hosted a panel discussion on bispecific antibodies and showcased its humanized mouse models to promote T-Cell Bispecific antibody and COVID-19 preclinic development. Hundreds of academic and industry researchers, as well as commercial partners from across the world, attended the conference, which is the largest in-person biologics event in London. Large pharmaceutical and biotech companies, contract research organizations (CROs), universities, and research institutions across the US are among the R&D communities that GPT serves with animal models and related services. GPT has partnered with these organizations in the US to enable shorter shipping times and lower costs. Inventive Sparks, Expanding Markets The key players operating the humanized mouse and rat model market involves Vitalstar Biotechnology, The Jackson Laboratory, Taconic Biosciences, Ingenious Targeting Laboratory, Horizon Discovery (Sage Labs), Hera Biolabs, Genoway, Crown Bioscience (Subsidiary Of Jsr Corporation), Champions Oncology, And Axeni. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
India.com
14-05-2025
- Health
- India.com
Dr. Manali Desai's Population Science Research to Advance Health Equity
Physician-scientist who is focusing on promoting HPV vaccine uptake, preventive screenings for cancer and cancer survivorship at The University of Texas Health Science Center at Houston, Texas. Her ecological study found that low-income areas had higher HPV vaccination coverage in Texas, also known as reverse disparity. Her research highlights that the insurance status and quality of patient-physician interaction impacts uptake of cervical cancer screenings. Additionally, her research reports younger, educated, higher-income internet users are the primary users of digital health and wellness apps for seeking cancer information. After completing her Bachelor of Medicine, Bachelor of Surgery (MBBS) along with an internship at Mahatma Gandhi Mission Institute of Health Sciences (MGMIHS) in Navi Mumbai, India, she moved to the US to seek graduate education in the field of public health. Fueled by a deep interest in population health and a desire to work at the intersection of clinical practice and public health research, she transitioned from clinical patient care to population science research, completing a Master of Public Health (MPH) in Epidemiology with a minor in Biostatistics from Texas A&M School of Public Health, College Station, TX and eventually pursuing her Ph.D. in Epidemiology at The University of Texas Health Science Center at Houston, TX in US. Dr. Desai has spent time teaching as well. She worked as a Teaching Assistant for several graduate-level public health courses, including Epidemiology, R programming, and data analysis. Along the way, she has guided many students helping them with their studies and also offering advice on how to work in research settings across different countries. Her research interests expanded further during her time at the Texas Department of State Health Services (DSHS) and Texas A&M University, where she contributed to projects related to HIV disparities and perinatal mental health, respectively. She further enhanced her analytical expertise by earning a professional certification in SAS Base programming. Today, she is a Ph.D. candidate in Epidemiology and an experienced researcher, educator, physician-scientist, mentor, and public health advocate. Manali's PhD research looked at how doctors and other healthcare workers in Texas feel about and recommend the HPV vaccine. She also studied the differences in HPV vaccination rates among cancer survivors in the U.S. Her work has led to several well-known publications and shows how strongly she cares about preventing cancer and making healthcare fair for everyone. Over the years, she has helped write many research papers that have appeared in respected journals. These papers cover topics like why some people don't get the HPV vaccine, how often people go for cancer screening, how doctors and patients talk to each other, and how telehealth is being used to support preventive care. Her research has also been shared at major public health events like the APHA, SER, and AACR, where it has drawn interest for highlighting important health issues. Manali found that people living in low-income areas sometimes had better HPV vaccination rates, which might be because more of them had insurance that paid for the vaccine. She also noticed that things like race and whether someone has health insurance can affect if they get checked for colorectal cancer. In another part of her work, she saw that younger people, those with more money or education, and people who use the internet often are more likely to use apps to learn about cancer. She also found that when doctors talk clearly and listen well, more women go for cervical cancer screening. All of these findings point to one big idea: making vaccines and cancer checks easier to get could really help people live healthier lives. Dr. Desai has a solid background in both clinical medicine and public health. This helped her land a competitive position as a Research Assistant at the University of Texas MD Anderson Cancer Center. With her expertise, she's working to make a real impact on global health, especially by reducing health inequalities and improving cancer prevention. Dr. Desai is passionate about fairness in healthcare and hopes to close the gap in public health policies through community research. 'Public health tells the stories of people, shown through data,' she shared. 'I want my research to connect the numbers with real change, especially for underserved communities around the world.' Disclaimer This article is from the Brand Desk. User discretion is advised.
